Hostname: page-component-77c89778f8-sh8wx Total loading time: 0 Render date: 2024-07-20T00:20:40.317Z Has data issue: false hasContentIssue false
  • English
  • Français

P03-101 N-Acetyl-cysteine in Augmentation to Atypical Antipsychotics Improves Cognitive Symptoms in Subjects with Schizophrenia

Published online by Cambridge University Press:  17 April 2020

A.E. Di Rosa ,
R. Cambria ,
M. Pata  and
M.C. Crescenti
A.E. Di Rosa
Affiliation:
Neuroscience and Psychiatry, University of Messina, Messina, Italy
R. Cambria
Affiliation:
Neuroscience and Psychiatry, University of Messina, Messina, Italy
M. Pata
Affiliation:
Neuroscience and Psychiatry, University of Messina, Messina, Italy
M.C. Crescenti
Affiliation:
Neuroscience and Psychiatry, University of Messina, Messina, Italy

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

Recent studies have shown that N-acetyl-cysteine added to neuroleptics might ameliorate negative and positive symptoms in schizophrenia. This could be related to the ability to interact with the cysteine/glutammate antiporter and to restore the intraneuronal rate of reduced gluthatione. This could also lead to an improvement of cognitive-executive functions.

Objectives

The aim of our study is the evaluation of co-administration of N-acetyl-cysteine (NAC) in cognitive functions in a sample of patients affected by schizophrenia diagnosed according to DSM IV-TR criteria, and treated with stable atypical antipsychotic therapy.

Materials & methods

We administered NAC (1800 mg/die) to 12 male patients, tested each patient at baseline and re-tested after 90 days using a battery of neurocognitive tests (Wisconsin Card Sorting Test, Verbal Fluency Test, Stroop Test) and PANSS scale for severity symptomatology evaluation. The results obtained in each test at baseline were compared with those at the end of the study.

Results

A significant improvement for WCST error numbers (sig. 0.049), VFT fonemic (sig. 0.049), PANSS positive (sig. 0.028), negative (sig. 0.002) and total (sig. 0.024) was observed.

 MeanSDError SDtsig.2-code
WCST error nr17.516.536.742.59.049*
VFT fonemic-1211.374.64-2.58.049*
VFT semantic-5.511.094.52-1.21.279
ΔT Stroop Test20.6734.7914.21.45.205
PANSS pos3.52.811.143.05.028*
PANSS neg4.51.870.765.89.002*
PANSS psycho0.54.761.940.26.807
PANSS total8.56.52.653.2.024*

Statistical correlations day 0-day 90 (sig. ≤ 0.05)

Conclusions

Our results show that co-administration of N-acetyl-cysteine added to atypical antipsychotic therapy improves the cognitive-executive functions. The effectiveness on reducing positive and negative symptoms was confirmed.

Type
Psychotic disorders / Schizophrenia
Information
European Psychiatry , Volume 25 , Issue S1: 18th European Congress of Psychiatry. February 27, March 2, 2010 - Munich, Germany , 2010 , 25-E1070
Copyright
Copyright © European Psychiatric Association 2010
Submit a response

Comments

No Comments have been published for this article.